Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200977 · ClinicalTrials.gov registry record
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 95
- Enrollment target
NCT03200977 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 95 participants.
The verdict
NCT03200977 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2022-06-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03200977
The ClinicalTrials.gov registry entry for NCT03200977 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03200977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03200977 about?
NCT03200977 is a clinical study titled "Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab". An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
What is the current status of trial NCT03200977?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2016-07-01. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03200977?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03200977?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.